VT-1161 clinical trials
Also written VT-1161.
How each study uses VT-1161 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the VT-1161 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 26 Apr 2022 · VIVJOA · NDA 215888 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2013 | 2 |
| 2015 | 2 |
| 2018 | 2 |
| 2019 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 1
Viamet (4) · Mycovia Pharmaceuticals Inc. (3) · University of Minnesota (1)
Studies
Open first, then newest update. How each study uses VT-1161 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Platform Trial for Salvage Consolidation Therapy in Dimorphic FungiNot yet recruitingPhase 2University of MinnesotaNCT07804368Written as Oteseconazole
- A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)CompletedPhase 3Mycovia Pharmaceuticals Inc.NCT03561701Written as Oteseconazole (VT-1161)
- A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)CompletedPhase 3Mycovia Pharmaceuticals Inc.NCT03562156Written as Oteseconazole (VT-1161)
- Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast InfectionsCompletedPhase 3Mycovia Pharmaceuticals Inc.NCT03840616Written as Oteseconazole (VT-1161) 150mg capsule
- A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the ToenailCompletedPhase 2ViametNCT02267356Written as VT-1161
- A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)CompletedPhase 2ViametNCT02267382Written as VT-1161
- A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)CompletedPhase 2ViametNCT01891331Written as VT-1161
- A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea PedisCompletedPhase 2ViametNCT01891305Written as VT-1161
Codes
What other systems call VT-1161 · ClinicalTrials.gg INT000255
- MeSH (NLM) C000599187VT-1161Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) VHH774W97NOTESECONAZOLEConfirmed FDA, NLM
- RxNorm 2602577One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000599187 | VT-1161 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | VHH774W97N | OTESECONAZOLE | Confirmed FDA, NLM |
| RxNorm | 2602577 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.